Seattle, Washington–(Newsfile Corp. – March 27, 2020) – CFN Media (OTCQB: CNFN), the leading agency and financial media network dedicated to the legalized North American cannabis industry announces publication of an article discussing how Israel has shipped the first cannabis export to the UK, marking a new era in Israeli cannabis.
Israel has long been an international center for cannabis research. THC, the psychoactive ingredient in cannabis, and CBD, the plant’s predominant non-psychoactive ingredient, were first isolated and defined by Israeli researcher Dr. Raphael Mechoulam in the early 1960s. Research continued there in the following decades, and the Israeli government has contributed greatly to the country’s prominence in the global cannabis industry.
In Israel, medical cannabis is legal while recreational use remains technically illegal, though the government decriminalized recreational use to some extent in 2017. Government agencies provide funding for cannabis research. In January 2019, the government passed a law to allow exports of medical cannabis, though the first export was announced a year later in January 2020. With that recent development, the table appears set for growth in the Israeli cannabis market.
Click below to view more on Isracann Biosciences – Israel’s First Pure Play Cannabis Firm
Cannot view this video? Visit:
Unmet Need in Europe
BOL Pharma is the Israeli company that announced the first export from the country, with a shipment destined for centers that specialize in the treatment of children with epilepsy and autism in the United Kingdom. The company’s CEO, Dr. Tamir Gedo, stated, “This is truly welcome news and a real breakthrough for the Israeli medical cannabis market. The Israeli cannabis industry has a huge competitive edge in the global arena, compared to many countries trying to enter the cannabis sector… Further opening of the market to exports will enable Israel to become a world leader in the coming years.”
The UK legalized medical cannabis in late 2018. Since then, patients have had a hard time getting prescribed treatments in a timely fashion, with most of the supply coming from foreign countries but facing restrictive regulations. As a result, in early March 2020, the UK government announced a change in import restrictions designed to increase the flow of timely medicinal products to registered patients.
This dynamic is common throughout Europe, with countries adopting medical programs without the infrastructure, both regulatory and physical, to provide supply to its own patients. Israel, with its strategic location combined with governmental commitment to the industry, is in prime position to pick up some of the slack.
Isracann Biosciences Poised to Move
Isracann Biosciences Inc. (CSE: IPOT) (OTC: ISCNF) is an Israeli-based cannabis company poised to enter both the Israeli domestic and the European export cannabis markets. The company is advancing its fully-funded 230,000 sq ft hybrid greenhouse cultivation project while also advancing a partnership with a late stage project consisting of approximately 200,000 sq ft of greenhouses located on over 880,000 sq ft of agricultural land. In conjunction with the cultivation projects, Isracann is developing European distribution channels while ensuring that all aspects of its business, from cultivation through processing and manufacturing, comply with European Union GMP regulations necessary for international trade.
While laying the groundwork for an extensive European export operation, the company is certainly not foregoing the burgeoning domestic opportunity in Israel. The country, as of late 2019, had about 46,000 registered patients. Isracann expects this number to roughly double by the end of 2020, by which time the company hopes to be harvesting and distributing products.
The company recently announced a joint venture agreement with two near-term farm operations in the Sharon Plain region of Israel. The IMC-compliant farms operate under preliminary cannabis nursery and cultivation licenses and are preparing to commence planting within weeks with 160,000 sq. ft. of greenhouse canopy on two million sq. ft. of private land. The move paves the way for the company to ramp up sales faster than it expected and could help drive near- and long-term shareholder value.
In a recent two-part interview with CFN Media, Isracann Biosciences CEO Darryl Jones outlined the company’s strategy, assets, and partnerships. He talked about some of the advantages inherent in the Israeli market (ideal climate for cultivation, regulatory environment, advanced research, widespread domestic use, proximity to Europe, etc.).
CEO Video Interview #1
Click Below to View Video Interview #1: Isracann Biosciences CEO Darryl Jones
Cannot view this video? Visit:
Click Below to View Video Interview Part #2: Isracann Biosciences CEO Darryl Jones
Cannot view this video? Visit:
The very first medical cannabis shipment from Israel to the UK marks a new era in the promising Israeli cannabis industry. With the country’s government backing research and development efforts, as well as implementing rules to encourage growth of the industry both domestically and internationally, Israel has cemented its place as a leader for the global cannabis market. The year ahead promises to be pivotal for both the industry in general, and for Isracann Biosciences in particular as the company executes its vision of a comprehensive farm-to-consumer cannabis company. Keep an eye out as the plan unfolds.
Click here to read the full article: https://bit.ly/2QNGwA1
About CFN Media
CFN Enterprises Inc. (OTCQB: CNFN) is the owner and operator of CFN Media, the leading agency and digital financial media network dedicated to the legal cannabis industry.
For Visitors and Viewers
CFN Media’s Cannabis Financial Network (CannabisFN.com) is the destination for savvy investors and business people profiting from the worldwide cannabis industry. Viewers will see breaking news, exclusive content and original programming involving the people, companies and investments shaping the industry.
For Cannabis Businesses & Companies
CFN Media is a leading agency and financial media network dedicated to the cannabis industry. We help private, pre-public and public cannabis companies in the US and Canada attract capital, investors and media attention.
Our powerful digital media and distribution platform conveys a company’s message and value proposition directly to accredited and retail investors and national media active in the North American cannabis markets.
Since 2013, CFN Media has enabled the world’s preeminent cannabis companies to thrive in the capital and public markets.
Learn how to become a CFN Media client company, brand or entrepreneur: https://www.cannabisfn.com/become-featured-company/
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/53879
Materia and Pure Ratios to Launch Award-Winning CBD Topicals into the UK Market
Materia (“Materia” or the “Company“), a medical cannabis and CBD wellness company focused on the European market, today announced an agreement with Pure Ratios Holdings Inc. (“Pure Ratios”), an award-winning CBD topical manufacturer and subsidiary of 4Front Ventures Corp (CSE: FFNT) (OTCQX: FFNTF), to distribute and market its products across Europe.
“Pure Ratios is an innovator, with a best-in-class transdermal patch, rooted in science and natural medicine. We are excited to be their European partner, with plans to launch in the UK as our first market,” said Deepak Anand, CEO of Materia. “The UK is currently Europe’s largest CBD market and consumers are developing brand preference for products they like and trust. The market research we have conducted, including consumer segmentation and brand mapping, has made clear the calibre of partners required for long-term success. With highly differentiated products, proven quality and an established track record with consumers, Pure Ratios fits this profile perfectly.”
Founded in 2015 and based in San Diego, California, Pure Ratios is known for combining holistic wellness concepts with CBD and other cannabinoids. Its award-winning line of CBD topical patches are sold through a network of over 1000 stores across the United States and through their expanding e-commerce and distribution platforms. Under the terms of the agreement, Materia will conduct sales and marketing for Pure Ratios’ hemp-derived CBD topical salve, topical roll-on, lip balm and 96-hour transdermal reservoir patch products. Materia will work directly with wholesalers, retailers, and direct to consumers channels in the UK.
“Our approach of combining modern cannabis science with natural holistic medicine is both unique and effective and that has helped establish Pure Ratios as one of the most reputable CBD brands in the US,” said Chad Conner, Co-Founder of Pure Ratios. “We selected Materia as our partner because they have the commercial acumen and regulatory expertise to help navigate the burgeoning European market opportunity for us to propel Pure Ratios into a leading global wellness brand.”
According to the Centre for Medical Cannabis, UK consumers are spending over £300 million a year on CBD products and the market is forecasted to grow to almost £1 billion by 20251. Demand for topicals is expected to exceed overall growth in the CBD market with a CAGR greater than 20%1. Key topical formats are balms and gels that are being used for muscle and joint relief, as well as skincare creams. The global CBD skincare market alone is expected to expand at a CAGR of 32.9% from 2019 to 2025, thereby reaching a value of approximately £1.4 billion (USD $1.7 billion) by 20252.
InnoCan Pharma Collaborate with Recipharm on its CBD Loaded Exosome (CLX) Treatments
Herzeliya, Israel and Calgary, Alberta–(Newsfile Corp. – July 9, 2020) – InnoCan Pharma Corporation (CNSX: INNO) (FSE: IP4) (the “Company” or “Innocan”), is pleased to announce its collaboration with Recipharm, Israel to synthesize and analyze cannabinoid loaded exosomes.
Recipharm unites more than 30 facilities across 10 different countries offering a range of services, mainly in two different operating areas, pharmaceutical development services and manufacturing services. Recipharm offers seamless tech transfer from Recipharm development facilities and provide commercial supply of a wide range of formulations. Recipharm has over 25 years of experience innovating and developing new technologies and processes for clinical applications. Recipharm’s facility in Israel, offers development services to a wide variety of clients from start-ups to large established companies. Recipharm offers a wide range of GMP-compliant services ranging from manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices.
Iris Bincovich, InnoCan’s CEO stated: “Working closely with the exceptional Recipharm team will allow InnoCan Pharma to devote efforts with the exosome technology production/loading technology while the work on the cannabinoids themselves will be done at Recipharm.”
Dr. Sylvia Kachalsky, site manager in Israel stated: “We are very exiting to work with InnoCan Pharma on this unique project who has a potential to be applied on large spectrum of different indications. The idea of loading Exosomes with Cannabinoids may open a wide window to different formulations, using the Exosome as a “targeted missile” leading the chosen Cannabinoid to its target.”
Prof. Dani Offen stated: “The development of the CLX- CBD loaded Exosome is very challenging but holding huge potential. Working with Recipharm will allow me and my team to be concentrating and putting all efforts at the Exosome production/characterization/loading side of the development process while knowing the analysis work is been done in one of the best labs we could chose. We are working with Recipharm in close collaboration on the development of this exiting technology and looking forward to achieve the milestones as we planned.”
About Innocan Pharma
The Company, through its wholly-owned subsidiary, Innocan Pharma Ltd. (“Innocan Pharma Israel“), is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD“) with other pharmaceutical ingredients. Innocan and Ramot at Tel Aviv University are collaborating on the development of a new exosome-based technology that targets both central nervous system indications and the COVID-19 coronavirus. CBD-loaded exosomes may hold the potential to provide a highly synergistic effect of anti-inflammatory properties and help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.
Innocan Pharma Israel has entered into a worldwide exclusive research and license agreement with Yissum Research and Development Company, the commercial arm of the Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. The Company, together with Prof. Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University, plans to test the liposome platform on several potential indications. The Company is also working on a dermal product integrating CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s annual turnover is approximately Euro 1.1 Billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For further information, please contact:
Innocan Pharma Corporation
Iris Bincovich, CEO
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution regarding forward-looking information
Certain information set forth in this news release is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan.
Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan are available under Innocan’s profile at www.sedar.com.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan Pharma does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/59362
TransCanna Announces Launch of Lyfted Apparel Line
Vancouver, British Columbia–(Newsfile Corp. – July 8, 2020) – TransCanna Holdings Inc. (CSE: TCAN) (“TransCanna” or the “Company“) announces that its wholly-owned subsidiary Lyfted Farms Inc. announces the launch of Lyfted Apparel line.
Lyfted Farms is thrilled to announce the launch of its own exclusive line of t-shirts, hoodies, caps, and other apparel and branded items. Lyfted Farms has contracted local artists to produce over 15 new designs that reflect the vibes of authentic California cannabis culture.
The new items can be found at www.lyftedfarms.com/apparel or on Instagram @lyftedfarmsapparel
Lyfted Farms has executed a Memorandum of Understanding with Raymond Willis, Founder, and CEO of Kingpin Skateboard and Apparel, to market and promote the new Lyfted Apparel line. Raymond brings more than 20 years of experience in the industry and favors exciting and creative ways to share the brand with a broader audience.
“I really love doing fun promotions where not only do you get to purchase the brands you love but also get to be a part of something bigger. Our first promotion for Lyfted Apparel will hit this month and feature a raffle the winner of which will spend an afternoon with Bay-Area Rapper Nump!” stated Raymond Willis.
In addition, the Company announces that it has entered into a Consulting Services Agreement with 1236686 B.C. Ltd. Pursuant to the Agreement, 1236686 B.C. Ltd. will provide consulting advice and services in connection with the development and operation of the corporate and financial affairs of the Company, its subsidiaries, and its affiliates. The Company will issue to 1236686 B.C. Ltd., 400,000 common shares for a deemed value of $296,000.
Additionally, the Company has elected not to renew the contract for its CFO, Michele Pillon. It is pleased to announce that Gary Khangura, CPA will act as “Interim” Chief Financial Officer as the Company seeks to recruit a Chief Financial Officer with a firm understanding of the cannabis industry in the California Marketplace. The Company thanks Ms. Pillon for her work during the Covid19 pandemic and assisting the Company in completing its audit during the extended deadlines.
The Company announces the resignation of Stephen Giblin as a director of the Company. Mr. Giblin has been appointed to the Company’s Advisory Board, the Company thanks Mr. Giblin for his time served.
About TransCanna Holdings Inc.
TransCanna Holdings Inc. is a California based, Canadian listed, Company building cannabis-focused brands for the California lifestyle, through its wholly-owned California subsidiaries.
On behalf of the Board of Directors
Bob Blink, CEO
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/59430
Cannabis3 weeks ago
RETRANSMISSION: Hemp, Inc. Announces that Its First Ever Great American Hempathon is in Full Swing
Cannabis4 weeks ago
Hemp, Inc. Rapidly Approaching $2 Million in Sales from Its Premium, High Quality Hemp Flower
Cannabis3 weeks ago
Banksy Collection Becomes Permanent Installation at Toronto’s Newest Cannabis Store
Cannabis3 weeks ago
Hemp, Inc. Announces Newly Enhanced King of Hemp Website
Cannabis4 weeks ago
From Solar to Hemp SinglePoint Continues to Drive Headlines and Increase Sales, Brand Recognition is Reaching New Heights as Articles and Interviews Publish
Cannabis4 weeks ago
XPhyto’s Diagnostic Partners Receive BMBF Grant for Infectious Disease Screening Tests
Cannabis4 weeks ago
Fountain Asset Corp. Announces Its Financial Results for the Quarter and Year Ended December 31, 2019
Cannabis3 weeks ago
XPhyto Therapeutics Corp.: Infectious Disease Oral Screening Test Advancement